Entrada Therapeutics (TRDA) Share-based Compensation (2020 - 2026)

Entrada Therapeutics' Share-based Compensation history runs 7 years deep, the most recent figure standing at $4.7 million for Q1 2026.

• In Q1 2026, Share-based Compensation fell 6.74% year-over-year to $4.7 million; the TTM figure through Mar 2026 stood at $19.3 million (changed 0.02% YoY), while the FY2025 annual figure was $19.6 million, up 9.46% from the prior year.
• Share-based Compensation was $4.7 million for Q1 2026 at Entrada Therapeutics, up from $4.4 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $5.1 million in Q3 2025 to a low of $1.8 million in Q1 2022.
• Historically, Share-based Compensation has averaged $3.8 million across 5 years, with a median of $3.8 million in 2023.
• The sharpest annual moves came in 2022 and 2025: Share-based Compensation soared 993.9% in 2022, then retreated 7.28% in 2025.
• A 5-year view of Share-based Compensation shows it stood at $2.9 million in 2022, then soared by 33.28% to $3.8 million in 2023, then grew by 22.36% to $4.7 million in 2024, then dropped by 7.28% to $4.4 million in 2025, then grew by 8.86% to $4.7 million in 2026.
• The last three Share-based Compensation figures came in at $4.7 million (Q1 2026), $4.4 million (Q4 2025), and $5.1 million (Q3 2025), per Business Quant data.